William Blair analyst Ryan Daniels has maintained their bullish stance on OPRX stock, giving a Buy rating on March 10.
Ryan Daniels has given his Buy rating due to a combination of factors including OptimizeRx’s strong financial performance in the fourth quarter of 2024. The company’s revenue and adjusted EBITDA both surpassed expectations, with revenue slightly exceeding the high end of the guidance and adjusted EBITDA outperforming by 17%. This robust performance highlights the company’s effective management and operational efficiency.
Moreover, the company’s revenue for the fourth quarter was $32.3 million, which not only surpassed the consensus estimate of $30.4 million but also represented a significant year-over-year increase of 14% and a sequential growth of 52%. Additionally, the gross profit margin improved by approximately 500 basis points compared to the previous year, reaching 68%. These positive trends, along with the introduction of 2025 guidance that aligns with market expectations, underpin Daniels’s confidence in the company’s future prospects and justify the Buy rating.
In another report released on March 10, Lake Street also maintained a Buy rating on the stock with a $11.00 price target.